Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticlePROCEEDINGS OF THE 21st ANNUAL MEETING OF THE SOCIETY OF BIOTHERAPEUTIC APPROACHES

Seizures and Tumor Progression in Glioma Patients with Uncontrollable Epilepsy Treated with Perampanel

SHUICHI IZUMOTO, MASAHARU MIYAUCHI, TAKAYUKI TASAKI, TAKESHI OKUDA, NOBUHIRO NAKAGAWA, NAOKI NAKANO, AMAMI KATO and MITSUGU FUJITA
Anticancer Research July 2018, 38 (7) 4361-4366; DOI: https://doi.org/10.21873/anticanres.12737
SHUICHI IZUMOTO
1Department of Neurosurgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sizumoto@med.kindai.ac.jp mfujita47@gmail.com
MASAHARU MIYAUCHI
1Department of Neurosurgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKAYUKI TASAKI
1Department of Neurosurgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKESHI OKUDA
1Department of Neurosurgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NOBUHIRO NAKAGAWA
1Department of Neurosurgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NAOKI NAKANO
1Department of Neurosurgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AMAMI KATO
1Department of Neurosurgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MITSUGU FUJITA
2Department of Microbiology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sizumoto@med.kindai.ac.jp mfujita47@gmail.com
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Excessive extracellular glutamate activates AMPA-type glutamate receptors (AMPA receptors) and induces seizures. Antagonistic activation of AMPA receptors inhibits epilepsy and glioma growth in in vitro and in vivo studies. This study was conducted to evaluate the clinical impacts of perampanel (PER), a novel AMPA receptor antagonist, on seizures and tumor progression in glioma patients with uncontrollable epilepsy. Patients and Methods: Twelve glioma patients with uncontrollable epilepsy were treated with PER. Seizure response, PER concentration, and tumor volume were assessed. Results: Obvious seizure control was observed in 10 analyzed patients (100%) and 6 patients (60%) became seizure-free. Median plasma concentrations of PER were 296 ng/ml in those with 4 mg/day PER treatment and 518 ng/ml in those with 8 mg/day PER treatment. High-intensity lesions in fluid-attenuated inversion recovery of magnetic resonance imaging (MRI) were volumetrically assessed to analyze tumor size. Volume reduction was detected within 6 months in correlation with increased plasma levels of PER. Conclusion: PER treatment was effective in uncontrollable epilepsy with gliomas. MRI images showed the inhibition of tumor growth.

  • Glioma
  • epilepsy
  • perampanel
  • AMPA receptor
  • antiepileptic drug

The central nervous system utilizes glutamate as a neurotransmitter. As excessive extracellular glutamate could elicit excitotoxicity, various mechanisms appear to strictly control extracellular concentrations of glutamate. Glioma cells release glutamate via glutamate/cystine antiporter exchange system (System Xc). The released glutamate further promotes survival and proliferation of glioma cells in an autocrine fashion (1). The glutamate released in the intercellular space also activates both synaptic and extra-synaptic AMPA-type glutamate receptor (AMPA receptor) and induces seizures (2, 3). It could also cause degeneration of normal brain cells and peritumoral edema (4, 5). During glioma treatment, approximately 50-90% of patients exhibit epilepsy, and 15-40% of patients acquire pharmaco-resistant epilepsy (6-8). Thus, there may be a close link between seizures and glioma progression. In this regard, recent data have shown that drug-resistant epilepsy (DRE) frequently occurs in glioma patients probably by mechanisms involving AMPA receptor activation that leads to seizure activity and glioma cell growth (9, 10). Glutamate receptor subunits expressed on tumor cells are closely linked to biochemical pathways that regulate malignant phenotypes (11, 12). The inhibition of AMPA receptors could ameliorate epilepsy and glioma growth (1, 5, 13). Based on these findings, a retrospective chart review of glioma patients with uncontrollable epilepsy treated with perampanel (PER), a novel AMPA receptor antagonist, was conducted.

Patients and Methods

Twelve patients with uncontrollable epilepsy despite administration of other anti-epileptic drugs (AED) were treated with PER consecutively at the Department of Neurosurgery, Kindai Hospital. Age over 18 years, glial tumor type, recurrent seizure activity at the time of initiating PER, and usage of at least one AEDs prior to the PER treatment were evaluated as patient characteristics. All patients with malignant glioma had been treated with Stupp regimen prior to the PER treatment. The PER treatment started at 2 mg per day before bedtime and was up-titrated by 2 mg increment with more than a week interval. If seizures stopped for a month, the same dose was maintained. Dose reduction of concurrent AEDs was considered when the patients stayed seizure-free for 6 weeks or more. The plasma concentration of PER (ng/ml) at the maintenance dose was measured by LSI Medience Corporation (14). The 50% reduction of seizure frequency or the achievement of seizure freedom was considered therapeutically effective. High-intensity lesions in fluid-attenuated inversion recovery (FLAIR) of magnetic resonance imaging (MRI) were volumetrically assessed to analyze the tumor volume and peritumoral edema for 6 months. Volumetry was conducted after image fusion via iPlan 3.0 (BrainLAB AG, Munich, Germany) based on manual sequencing of FLAIR images according to the method previously described (15, 16) and the volume changes within 6 months were evaluated. The correlation between the volume changes and the plasma concentrations of PER was also evaluated.

Results

Twelve patients (8 males and 4 females, median age of 59 years) were treated with PER. Patient characteristics including types of tumor and seizure are shown in Table I. Two patients were grade 2 glioma (1 diffuse astrocytoma and 1 oligoastrocytoma), 8 patients were grade 3 glioma (3 anaplastic astrocytoma and 5 anaplastic oligodendroglioma), and 2 patients were grade 4 glioma (glioblastoma multiforme / GBM). Concomitant drugs are described in Table II. During the PER administration, temozolomide (TMZ) was used in 6 patients, and bevacizumab was used in 3 patients.

Patients with one or two AEDs were treated with PER. Nine patients were treated with 4 mg of PER and 3 patients were treated with 8 mg as maintenance doses. A patient (Case 2) discontinued PER because of intolerable dizziness at a dose of 4 mg. Another patient (Case 10) died due to intratumor hemorrhage caused by head injury. These two patients were excluded due to lack of the therapeutic efficacy. PER was down-titrated from 6 to 4 mg in Case 3 because of sluggish speech and dizziness after alcohol intake. After down-titration to 4 mg, these symptoms disappeared but the seizure was well controlled. Ten patients including Case 3 continued the PER treatment and their data were included in the efficacy analysis. Seizure aggravation was not observed in response to PER.

All 10 patients achieved more than 50% seizure reduction. Among them, 6 patients became seizure-free. Seven patients were maintained with 4 mg/day of PER and 3 patients were maintained with 8 mg/day of PER. Doses of concomitant AEDs were reduced in 4 patients because they were seizure-free for 6 weeks or more.

The median plasma concentration of PER was 296 ng/ml in glioma patients with 4 mg/day PER, and 518 ng/ml in glioma patients with 8 mg/day PER. However, the plasma concentration of PER in the patients with 4 mg/day PER had a wide range (range=110-906 ng/ml; Table II and Figure 1). Doses of other AEDs were all in the effective range (data not shown). Tumor volume and peritumoral edema within 6 months were volumetrically analyzed by MRI-FLAIR images, and the volume changes were evaluated. The tumor volume decreased in eight of 9 patients during 6 months by FLAIR image (Figure 2) and increased in one (Case 9) of 9 patients. The other one patient was excluded from analysis because of no detectable FLAIR-high lesion on MRI. Figure 2 shows the 2D-MRI images of representative 5 responding patients before and 6 months after the initiation of the PER treatment.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Patient characteristics.

The volume changes of the FLAIR images within 6 months were compared with the plasma concentrations of PER. Regression analysis indicated that the volume reduction was correlated with the plasma concentration of PER (R2=0.6909; Figure 3). Higher plasma PER levels were found in 3 patients that showed high reduction ratio.

Discussion

PER was administered to a series of patients with uncontrollable epilepsy related to both low- and high-grade gliomas. Among them, 10 patients achieved more than 50% seizure reduction and 6 patients became seizure-free. Vecht et al. (17) have reported that 50% of their glioma patients achieved seizure freedom and that 25% experienced more than 50% seizure reduction, which is consistent with our results. In a randomized phase 3 study in which patients with partial-onset DREs were treated with PER, 36% of the patients achieved 50% seizure reduction at a dose of 8 mg/day (18). In real-world clinical experience, PER promoted more than 50 seizure reduction in 48.6% of patients, and 14.3% became seizure-free (19). In addition, PER appears to control seizures in glioma patients more effectively than those without glioma (8, 20, 21). Smaller efficacy size in DRE patients without glioma might be attributable to the inclusion of highly drug-resistant population.

Seizure occurrence in glioma patients is related to high peritumoral glutamate concentrations. The excessive glutamate concentrations in peritumor lesions might be attributable to its release from glioma cells through the System Xc (1, 3, 21). This glutamate release could also occur in extra-synaptic space. Ectopically-released glutamate might remain in situ due to the lack of sufficient system for glutamate clearance. Therefore, the direct antagonistic activity of PER against peritumoral glutamate appears to promote the prominent antiepileptic effects in this population. Our results indicate that all 5 patients with uncontrollable secondarily generalized seizure achieved more than 50% reduction in seizure frequency. Seven of 9 patients with 4 mg PER also achieved more than 50% reduction of seizure frequency, supporting the glioma-specific etiology of seizures.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Summary of results.

Only one patient was excluded from the PER treatment because of its side-effects. Another patient also showed side effects at 6 mg/day of PER but recovered after dose reduction to 4 mg. Over the 6-month evaluation period, a dropout from the PER treatment was 1 out of 12 patients (8.3%), which indicates that the tolerability of PER was acceptable.

All patients were treated with at least one AED prior to the PER treatment, and the median PER dose was 4 mg, which is the minimal efficacious dose of PER in DRE. Earlier use and lower doses might reduce the incidence and severity of the side effects and increase retention.

Talampanel was formerly developed as a noncompetitive AMPA antagonist prior to PER but not marketed as an AED because of its short terminal half-life and association with several adverse events including ataxia and dizziness. Nevertheless, it demonstrated therapeutic efficacy in patients with partial-onset DREs (22). For glioma treatment, talampanel along with radiotherapy and TMZ has exhibited survival benefit in patients with newly diagnosed GBM (23) but had no significant activity as a single agent in recurrent malignant gliomas (24). Thereafter, PER has been developed as a novel non-competitive AMPA-receptor antagonist and approved as adjunctive therapy for seizure treatment. PER has excellent brain penetration, a long half-life and drug concentration profile compared with talampanel (25, 26).

We measured the plasma level of PER at steady state when the dose of PER was maintained for at least two weeks. The median plasma concentration of PER was 296 ng/ml in glioma patients with 4 mg/day PER treatment and 518 ng/ml in glioma patients with 8 mg/day PER treatment. These values are similar to those in previous Japanese studies (27, 28). Our data indicate that the plasma concentration of PER in patients with 4 mg/day PER had a wide range (110-906 ng/ml). Other AED doses were all within effective range (data not shown). One patient (Case 9) treated with 4 mg/day PER and 225 mg/day phenytoin had low plasma PER concentrations. It is probably because phenytoin is an enzyme (CYP3A4)-inducing antiepileptic drug that enhances the clearance of PER (29).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Plasma concentrations of PER. Administration dose of PER and plasma concentration of PER in each patient are plotted.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Radiographical responses to PER. Five cases of MRI-FLAIR images before and 6 months after the treatment of PER. High-intensity lesions decreased in size. A: Case 8 including Gd-enhanced T1WI, B: Case 3, C: Case 4, D: Case 5, E: Case 12.

A large inter-individual difference of PER plasma concentration was found in our patients. Known drugs or foods that inhibit CYP3A metabolites were not administered to patients with higher plasma concentrations of PER. As the inter-individual and ethnic differences are known for the expression levels of CYP3A, these factors might be responsible for the large variation of plasma concentration of PER in this study (30).

Tumor growth and peritumoral edema within 6 months were analyzed by the volume changes of high-intensity lesion of MRI-FLAIR images. A strong correlation has been revealed between 2D and 3D volumetric measurements (31), and 3D images are known to be more informative. Therefore, we used 3D measurements in this study. Shrinkage of the high-intensity lesion on MRI-FLAIR was detected in 8 of 10 patients treated with PER. The volume reduction was well correlated with the plasma concentration of PER.

The results of this study suggest the inhibitory effects of PER on tumor progression and/or peritumoral brain edema. Of note, all the patients with extremely high plasma PER levels exhibited glioma growth inhibition. One explanation for the close link between seizures inhibition and glioma growth inhibition is elevated extracellular glutamate levels in the peri-glial and peri-neuronal spaces that may cause the excessive activities of AMPA-receptors in both conditions (1, 13). In vitro and in vivo studies have shown that AMPA receptor inhibition arrests glioma growth and invasion (9, 32, 33). In a clinical case report from Germany, a PER-treated GBM patient without isocitrate dehydrogenase (IDH) gene mutation and O6-methylguanine DNA methyltransferase (MGMT) gene expression survived for a year longer (34). PER may provide the therapeutic opportunities for both seizure control and anti-tumor effects as a non-competitive AMPA inhibitor (23), although the cytotoxic effect of PER against glioma cells may not be cytocidal but cytostatic. In this study, 6 patients had TMZ and 3 patients had bevacizumab along with PER; these chemotherapeutic agents may have influenced glioma growth inhibition. However, TMZ was maintained at least 3 months prior to the PER treatment and the MR images did not change during this period. Izquierdo et al. (35) have reported that mean tumor diameter of low-grade glioma progressively decreased in most patients (94.4%) with a median slope of −5.7 mm/year (range=−14.84 to −0.85 mm/year) and for a median duration of 23 months after TMZ treatment. In GBM, median time to progression according to the Response Assessment in Neuro-Oncology (RANO) criteria was 6.4 months (36). These results suggested that our patients had refractory tumors against TMZ. Regarding bevacizumab, Case 12 also showed a decrease in gadolinium (Gd)-enhanced lesions but not in the FLAIR-high lesions during the bevacizumab treatment. However, the FLAIR-high lesion decreased after the administration of PER. In Case 8 without bevacizumab, Gd-enhanced lesions slightly decreased, and FLAIR-high lesion obviously decreased in response to the PER treatment. Corticosteroids (1 mg of betamethasone) were used in 3 patients, but their dose was unchanged during the 6 months. These results suggested that bevacizumab had minimal effect on the results in this study and that the underlying mechanism for the reduction of tumor volume in response to the PER might be an antitumor effect rather than a mere reduction of peritumoral edema.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Correlation between MRI-based volume changes and plasma concentrations of PER. Tumor growth and peritumoral edema for 6 months were analyzed by 3D-MRI with volumetric measurements of high-intensity lesions of MRI-FLAIR images (by Brain Labo software iPlan Cranial 3.0), and the volume reduction was compared to the plasma concentration of PER. The volume reduction ratios (%) of FLAIR images (=MRI 6 months after the initiation of PER/MRI immediately before the seizure that required the administration of PER) were on the Y-axis, and the plasma concentrations of PER were on the X-axis. The volume reduction (%) correlated with the plasma concentration of PER (R2=0.6909) by regression analysis.

In conclusion, more than 50% seizure reduction and seizure-freedom were observed in evaluated patients with uncontrollable epilepsy treated with PER. PER treatment for tumor-related uncontrollable epilepsy was more effective than for those with tumor-irrelevant uncontrollable epilepsy. Furthermore, MRI images of glioma patients showed tumor growth inhibition and/or peritumoral brain edema reduction in correlation with the plasma concentrations of PER. These favorable results warrant a randomized study of PER to determine seizure and tumor responses in uncontrollable epilepsy with glioma.

Acknowledgements

This work was supported by the following JSPS KAKENHI grants: 17K10881 (S.I.) and 16K10348 (M.F.). The Authors thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

Footnotes

  • Conflicts of Interest

    The Authors declare that they have no conflict of interest regarding this study.

  • Received April 11, 2018.
  • Revision received June 5, 2018.
  • Accepted June 6, 2018.
  • Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. de Groot J,
    2. Sontheimer H
    : Glutamate and the biology of gliomas. Glia 59: 1181-1189, 2011.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Huberfeld G,
    2. Vecht CJ
    : Seizures and gliomas – towards a single therapeutic approach. Nat Rev Neurol 12: 204-216, 2016.
    OpenUrl
  3. ↵
    1. Neal A,
    2. Yuen T,
    3. Bjorksten AR,
    4. Kwan P,
    5. O'Brien TJ,
    6. Morokoff A
    : Peritumoural glutamate correlates with post-operative seizures in supratentorial gliomas. J Neurooncol 129: 259-267, 2016.
    OpenUrl
  4. ↵
    1. Savaskan NE,
    2. Fan Z,
    3. Broggini T,
    4. Buchfelder M,
    5. Eyüpoglu IY
    : Neurodegeneration and the Brain Tumor Microenvironment. Curr Neuropharmacol 13: 258-265, 2015.
    OpenUrl
  5. ↵
    1. Westergren I,
    2. Johansson BB
    : Blockade of AMPA receptors reduces brain edema following opening of the blood-brain barrier. J Cereb Blood Flow Metab 13: 603-608, 1993.
    OpenUrlCrossRefPubMed
  6. ↵
    1. van Breemen MS,
    2. Wilms EB,
    3. Vecht CJ
    : Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 6: 421-430, 2007.
    OpenUrlCrossRefPubMed
    1. Pallud J,
    2. Audureau E,
    3. Blonski M,
    4. Sanai N,
    5. Bauchet L,
    6. Fontaine D,
    7. Mandonnet E,
    8. Dezamis E,
    9. Psimaras D,
    10. Guyotat J,
    11. Peruzzi P,
    12. Page P,
    13. Gal B,
    14. Párraga E,
    15. Baron MH,
    16. Vlaicu M,
    17. Guillevin R,
    18. Devaux B,
    19. Duffau H,
    20. Taillandier L,
    21. Capelle L,
    22. Huberfeld G
    : Epileptic seizures in diffuse low-grade gliomas in adults. Brain 137: 449-462, 2014.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Armstrong TS,
    2. Grant R,
    3. Gilbert MR,
    4. Lee JW,
    5. Norden AD
    : Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy. Neuro Oncol 18: 779-789, 2016.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Ishiuchi S,
    2. Yoshida Y,
    3. Sugawara K,
    4. Aihara M,
    5. Ohtani T,
    6. Watanabe T,
    7. Saito N,
    8. Tsuzuki K,
    9. Okado H,
    10. Miwa A,
    11. Nakazato Y,
    12. Ozawa S
    : Ca2+-permeable AMPA receptors regulate growth of human glioblastoma via Akt activation. J Neurosci 27: 7987-8001, 2007.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Lee SG,
    2. Su ZZ,
    3. Emdad L,
    4. Sarkar D,
    5. Franke TF,
    6. Fisher PB
    : Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling. Oncogene 27: 1114-1121, 2008.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Luksch H,
    2. Uckermann O,
    3. Stepulak A,
    4. Hendruschk S,
    5. Marzahn J,
    6. Bastian S,
    7. Staufner C,
    8. Temme A,
    9. Ikonomidou C
    : Silencing of selected glutamate receptor subunits modulates cancer growth. Anticancer Res 31: 3181-3192, 2011.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Stepulak A,
    2. Luksch H,
    3. Uckermann O,
    4. Sifringer M,
    5. Rzeski W,
    6. Polberg K,
    7. Kupisz K,
    8. Klatka J,
    9. Kielbus M,
    10. Grabarska A,
    11. Marzahn J,
    12. Turski L,
    13. Ikonomidou C
    : Glutamate receptors in laryngeal cancer cells. Anticancer Res 31: 565-573, 2011.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Robel S,
    2. Sontheimer H
    : Glia as drivers of abnormal neuronal activity. Nat Neurosci 19: 28-33, 2016.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Mano Y,
    2. Takenaka O,
    3. Kusano K
    : High-performance liquid chromatography-tandem mass spectrometry method for the determination of perampanel, a novel α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist in human plasma. J Pharm Biomed Anal 107: 56-62, 2015.
    OpenUrl
  14. ↵
    1. Pala A,
    2. Brand C,
    3. Kapapa T,
    4. Hlavac M,
    5. König R,
    6. Schmitz B,
    7. Wirtz CR,
    8. Coburger J
    : The value of intraoperative and early postoperative magnetic resonance imaging in low-grade glioma surgery: A Retrospective Study. World Neurosurg 93: 191-197, 2016.
    OpenUrl
  15. ↵
    1. Marinelli JP,
    2. Van Gompel JJ,
    3. Link MJ,
    4. Moore EJ,
    5. Price DL,
    6. Lees KA,
    7. Kaczor MW,
    8. Janus JR
    : Volumetric analysis of olfactory neuroblastoma skull base laterality and implications on neck disease. Laryngoscope 128: 864-870, 2018.
    OpenUrl
  16. ↵
    1. Vecht C,
    2. Duran-Peña A,
    3. Houillier C,
    4. Durand T,
    5. Capelle L,
    6. Huberfeld G
    : Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations. J Neurooncol 133: 603-607, 2017.
    OpenUrl
  17. ↵
    1. Krauss GL,
    2. Serratosa JM,
    3. Villanueva V,
    4. Endziniene M,
    5. Hong Z,
    6. French J,
    7. Yang H,
    8. Squillacote D,
    9. Edwards HB,
    10. Zhu J,
    11. Laurenza A
    : Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 78: 1408-1415, 2012.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Kurth C,
    2. Kockelmann E,
    3. Steinhoff BJ
    : Clinical outcomes of perampanel vs. lacosamide in cohorts of consecutive patients with severely refractory epilepsies – A monocentric retrospective analysis of systematically collected data from the German Kork Epilepsy Center. Seizure 45: 47-51, 2017.
    OpenUrl
  19. ↵
    1. French JA,
    2. Krauss GL,
    3. Biton V,
    4. Squillacote D,
    5. Yang H,
    6. Laurenza A,
    7. Kumar D,
    8. Rogawski MA
    : Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 79: 589-596, 2012.
    OpenUrlCrossRefPubMed
  20. ↵
    1. French JA,
    2. Krauss GL,
    3. Steinhoff BJ,
    4. Squillacote D,
    5. Yang H,
    6. Kumar D,
    7. Laurenza A
    : Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 54: 117-125, 2013.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Chappell AS,
    2. Sander JW,
    3. Brodie MJ,
    4. Chadwick D,
    5. Lledo A,
    6. Zhang D,
    7. Bjerke J,
    8. Kiesler GM,
    9. Arroyo S
    : A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology 58: 1680-1682, 2002.
    OpenUrlCrossRef
  22. ↵
    1. Grossman SA,
    2. Ye X,
    3. Chamberlain M,
    4. Mikkelsen T,
    5. Batchelor T,
    6. Desideri S,
    7. Piantadosi S,
    8. Fisher J,
    9. Fine HA
    : Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J Clin Oncol 27: 4155-4161, 2009.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Iwamoto FM,
    2. Kreisl TN,
    3. Kim L,
    4. Duic JP,
    5. Butman JA,
    6. Albert PS,
    7. Fine HA
    : Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas. Cancer 116: 1776-1782, 2010.
    OpenUrlPubMed
  24. ↵
    1. Hanada T,
    2. Hashizume Y,
    3. Tokuhara N,
    4. Takenaka O,
    5. Kohmura N,
    6. Ogasawara A,
    7. Hatakeyama S,
    8. Ohgoh M,
    9. Ueno M,
    10. Nishizawa Y
    : Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 52: 1331-1340, 2011.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Hibi S,
    2. Ueno K,
    3. Nagato S,
    4. Kawano K,
    5. Ito K,
    6. Norimine Y,
    7. Takenaka O,
    8. Hanada T,
    9. Yonaga M
    : Discovery of 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (perampanel): a novel, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) receptor antagonist. J Med Chem 55: 10584-10600, 2012.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Yamamoto Y,
    2. Usui N,
    3. Nishida T,
    4. Takahashi Y,
    5. Imai K,
    6. Kagawa Y,
    7. Inoue Y
    : Therapeutic Drug Monitoring for Perampanel in Japanese Epilepsy Patients: Influence of Concomitant Antiepileptic Drugs. Ther Drug Monit 39: 446-449, 2017.
    OpenUrl
  27. ↵
    1. Gidal BE,
    2. Ferry J,
    3. Majid O,
    4. Hussein Z
    : Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures. Epilepsia 54: 1490-1497, 2013.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Gidal BE,
    2. Laurenza A,
    3. Hussein Z,
    4. Yang H,
    5. Fain R,
    6. Edelstein J,
    7. Kumar D,
    8. Ferry J
    : Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy. Neurology 84: 1972-1980, 2015.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Yamaori S,
    2. Yamazaki H,
    3. Iwano S,
    4. Kiyotani K,
    5. Matsumura K,
    6. Saito T,
    7. Parkinson A,
    8. Nakagawa K,
    9. Kamataki T
    : Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers. Xenobiotica 35: 69-83, 2005.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Wang MY,
    2. Cheng JL,
    3. Han YH,
    4. Li YL,
    5. Dai JP,
    6. Shi DP
    : Measurement of tumor size in adult glioblastoma: classical cross-sectional criteria on 2D MRI or volumetric criteria on high resolution 3D MRI. Eur J Radiol 81: 2370-2374, 2012.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Takano T,
    2. Lin JH,
    3. Arcuino G,
    4. Gao Q,
    5. Yang J,
    6. Nedergaard M
    : Glutamate release promotes growth of malignant gliomas. Nat Med 7: 1010-1015, 2001.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Ishiuchi S,
    2. Tsuzuki K,
    3. Yoshida Y,
    4. Yamada N,
    5. Hagimura N,
    6. Okado H,
    7. Miwa A,
    8. Kurihara H,
    9. Nakazato Y,
    10. Tamura M,
    11. Sasaki T,
    12. Ozawa S
    : Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med 8: 971-978, 2002.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Rösche J,
    2. Piek J,
    3. Hildebrandt G,
    4. Grossmann A,
    5. Kirschstein T,
    6. Benecke R
    : Perampanel in the treatment of a patient with glioblastoma multiforme without IDH1 mutation and without MGMT promotor methylation. Fortschr Neurol Psychiatr 83: 286-289, 2015.
    OpenUrl
  34. ↵
    1. Izquierdo1 C,
    2. Alentorn A,
    3. Idbaih A,
    4. Simó M,
    5. Kaloshi G,
    6. Ricard D,
    7. Barritault M,
    8. Meyronet D,
    9. Bruna J,
    10. Honnorat J,
    11. Delattre JY,
    12. Ducray F
    : Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics. J Neurooncol 136: 533-539, 2018.
    OpenUrl
  35. ↵
    1. Tensaouti F,
    2. Khalifa J,
    3. Lusque A,
    4. Plas B,
    5. Lotterie JA,
    6. Berry I,
    7. Laprie A,
    8. Cohen-Jonathan Moyal E,
    9. Lubrano V
    : Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma. Neuroradiology 59: 1013-1020, 2017.
    OpenUrl
PreviousNext
Back to top

In this issue

Anticancer Research: 38 (7)
Anticancer Research
Vol. 38, Issue 7
July 2018
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Seizures and Tumor Progression in Glioma Patients with Uncontrollable Epilepsy Treated with Perampanel
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Seizures and Tumor Progression in Glioma Patients with Uncontrollable Epilepsy Treated with Perampanel
SHUICHI IZUMOTO, MASAHARU MIYAUCHI, TAKAYUKI TASAKI, TAKESHI OKUDA, NOBUHIRO NAKAGAWA, NAOKI NAKANO, AMAMI KATO, MITSUGU FUJITA
Anticancer Research Jul 2018, 38 (7) 4361-4366; DOI: 10.21873/anticanres.12737

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Seizures and Tumor Progression in Glioma Patients with Uncontrollable Epilepsy Treated with Perampanel
SHUICHI IZUMOTO, MASAHARU MIYAUCHI, TAKAYUKI TASAKI, TAKESHI OKUDA, NOBUHIRO NAKAGAWA, NAOKI NAKANO, AMAMI KATO, MITSUGU FUJITA
Anticancer Research Jul 2018, 38 (7) 4361-4366; DOI: 10.21873/anticanres.12737
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Seizures Prior to Radiotherapy of Gliomas: Prevalence, Risk Factors and Survival Prognosis
  • Significance of Elevated HMGB1 Expression in Pituitary Apoplexy
  • Perampanel Inhibits Neuroblastoma Cell Proliferation Through Down-regulation of AKT and ERK Pathways
  • Google Scholar

More in this TOC Section

PROCEEDINGS OF THE 21st ANNUAL MEETING OF THE SOCIETY OF BIOTHERAPEUTIC APPROACHES

  • Evaluation of a Hypertensive Rat Model Using Peripheral Blood Neutrophil Activity, Phagocytic Activity and Oxidized LDL Evaluation
  • Possible Application of Ascites-infiltrating Gamma-delta T Cells for Adoptive Immunotherapy
  • Catumaxomab with Activated T-cells Efficiently Lyses Chemoresistant EpCAM-positive Triple-negative Breast Cancer Cell Lines
Show more PROCEEDINGS OF THE 21st ANNUAL MEETING OF THE SOCIETY OF BIOTHERAPEUTIC APPROACHES

Clinical Studies

  • Role of 1p/19q Codeletion in Diffuse Low-grade Glioma Tumour Prognosis
  • Identification of Patients With Glioblastoma Who May Benefit from Hypofractionated Radiotherapy
  • Optimal Treatment of Hormone Receptor-positive Advanced Breast Cancer Patients With Palbociclib
Show more Clinical Studies

Similar Articles

Keywords

  • Glioma
  • epilepsy
  • perampanel
  • AMPA receptor
  • antiepileptic drug
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire